Loading…
Lobbying Spend
—
Filings
51
Firms Hired
2
Active Period
2005–2015
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Preserving Access to Life-Saving Medications Act of 2011
2012 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products. Lobbied for inclusion of provisions in S. 3187, the Food & Drug Administration Safety & Innovation Act and HR 5651, the Food & Drug Administration Reform Act of 2012. Also worked on provisions in those billes that: provide for accelerated approval, modify FDA Advisory Committee Rules, create a voucher program to incentivize companies to develop products for rare pediatric cancer, and extend enantiomer exclusivity program.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 2245
Drug Shortage Prevention Act of 2012
2012 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products. Lobbied for inclusion of provisions in S. 3187, the Food & Drug Administration Safety & Innovation Act and HR 5651, the Food & Drug Administration Reform Act of 2012. Also worked on provisions in those billes that: provide for accelerated approval, modify FDA Advisory Committee Rules, create a voucher program to incentivize companies to develop products for rare pediatric cancer, and extend enantiomer exclusivity program.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3839
Food and Drug Administration Reform Act of 2012
2012 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products. Lobbied for inclusion of provisions in S. 3187, the Food & Drug Administration Safety & Innovation Act and HR 5651, the Food & Drug Administration Reform Act of 2012. Also worked on provisions in those billes that: provide for accelerated approval, modify FDA Advisory Committee Rules, create a voucher program to incentivize companies to develop products for rare pediatric cancer, and extend enantiomer exclusivity program.
Client expense: — · Firm income: $40,000
Matched citations: HR 5651
Preserving Access to Life-Saving Medications Act of 2011
2012 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products. Lobbied for inclusion of provisions in S. 3187, the Food & Drug Administration Safety & Innovation and HR 5651, the Food & Drug Administration Reform Act of 2012. Also worked on provisions in those billes that: provide for accelerated approval, modify FDA Advisory Committee Rules, create a voucher program to incentivize companies to develop products for rare pediatric cancer, and extend enantiomer exclusivity program.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 2245
Drug Shortage Prevention Act of 2012
2012 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products. Lobbied for inclusion of provisions in S. 3187, the Food & Drug Administration Safety & Innovation and HR 5651, the Food & Drug Administration Reform Act of 2012. Also worked on provisions in those billes that: provide for accelerated approval, modify FDA Advisory Committee Rules, create a voucher program to incentivize companies to develop products for rare pediatric cancer, and extend enantiomer exclusivity program.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3839
Food and Drug Administration Reform Act of 2012
2012 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products. Lobbied for inclusion of provisions in S. 3187, the Food & Drug Administration Safety & Innovation and HR 5651, the Food & Drug Administration Reform Act of 2012. Also worked on provisions in those billes that: provide for accelerated approval, modify FDA Advisory Committee Rules, create a voucher program to incentivize companies to develop products for rare pediatric cancer, and extend enantiomer exclusivity program.
Client expense: — · Firm income: $40,000
Matched citations: HR 5651
Preserving Access to Life-Saving Medications Act of 2011
2012 · first_quarter · Firm: HOLLAND & KNIGHT LLP
Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 2245
Drug Shortage Prevention Act of 2012
2012 · first_quarter · Firm: HOLLAND & KNIGHT LLP
Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3839
Prepare advocacy materials to be used for lobbying on issues related to development of drugs for rare diseases, reimbursement of products, and FDA review and approval of products for rare diseases and other conditions. Prepared materials regarding S. 296, Preserving Access to Life Saving Medicines Act; Met with congressional staff regarding same shortage legislation. Developed advocacy materials re: HR 3737 "Unlocking Live Saving Rare Diseases Act.
Client expense: — · Firm income: $40,000
Matched citations: HR 3737
American Middle Class Tax (AMT) Relief Act of 2007
2010 · first_quarter · Firm: HOLLAND & KNIGHT LLP
Worked to keep provisions regarding biosimilar approval pathway in HR 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Reconciliation Act of 2010; Coverage of Elaprase in state Medicaid Plan.
Client expense: — · Firm income: $40,000
Matched citations: HR 3590
American Middle Class Tax (AMT) Relief Act of 2007
2010 · first_quarter · Firm: HOLLAND & KNIGHT LLP
Worked to keep provisions regarding biosimilar approval pathway in HR 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Reconciliation Act of 2010; Coverage of Elaprase in state Medicaid Plan.
Client expense: — · Firm income: $40,000
Matched citations: HR 3590
American Middle Class Tax (AMT) Relief Act of 2007
2009 · fourth_quarter · Firm: HOLLAND & KNIGHT LLP
Worked to keep provisions regarding biosimilar approval pathway in HR 3590, Patient Protection and Affordable Care Act.
Client expense: — · Firm income: $30,000
Matched citations: HR 3590
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Worked on H.R. 1548, Pathway for Biosimilars Act; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act; seek amendment regarding biologics in rare diseases; supported amendment incorporating these provisions into H.R. 3200, America's Affordable Health Choices Act of 2009 and the Affordable Health Choices Act in the Senate.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1427
Worked on H.R. 1548, Pathway for Biosimilars Act; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act; seek amendment regarding biologics in rare diseases; supported amendment incorporating these provisions into H.R. 3200, America's Affordable Health Choices Act of 2009 and the Affordable Health Choices Act in the Senate.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1548
America's Affordable Health Choices Act of 2009
2009 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Worked on H.R. 1548, Pathway for Biosimilars Act; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act; seek amendment regarding biologics in rare diseases; supported amendment incorporating these provisions into H.R. 3200, America's Affordable Health Choices Act of 2009 and the Affordable Health Choices Act in the Senate.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3200
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Worked on HR 1548, Pathway for Biosimilars Act; HR 1427, Promoting Innovation and Access to Life-Saving Medicine Act; seek amendment regarding biologics in rare diseases.
Client expense: — · Firm income: $30,000
Matched citations: HR 1427
Pathway for Biosimilars Act
2009 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Worked on HR 1548, Pathway for Biosimilars Act; HR 1427, Promoting Innovation and Access to Life-Saving Medicine Act; seek amendment regarding biologics in rare diseases.
Client expense: — · Firm income: $30,000
Matched citations: HR 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: HOLLAND & KNIGHT LLP
Worked on HR 1548, Pathway for Biosimilars Act; HR 1427, Promoting Innovation and Access to Life-Saving Medicine Act
Client expense: — · Firm income: $10,000
Matched citations: HR 1427
Worked on HR 1548, Pathway for Biosimilars Act; HR 1427, Promoting Innovation and Access to Life-Saving Medicine Act
Client expense: — · Firm income: $10,000
Matched citations: HR 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: HOLLAND & KNIGHT LLP
Worked on HR 1548, Pathway for Biosimilars Act; HR 1427, Promoting Innovation and Access to Life-Saving Medicine Act
Client expense: — · Firm income: —
Matched citations: HR 1427
Worked on HR 1548, Pathway for Biosimilars Act; HR 1427, Promoting Innovation and Access to Life-Saving Medicine Act
Client expense: — · Firm income: —
Matched citations: HR 1548
Source: Senate LDA